Cefuroxime is a new semisynthetic cephalosporin (O'Callaghan et al. 1976) with favourable pharmacokinetics (Foord 1976 ) and a broad antibacterial spectrum. A low degree of serum protein binding and high metabolic stability are coupled with resistance to ,B-lactamase hydrolysis. Because of its increased antimicrobial activity against Enterobacteriaceaw shown in vitro (Richmond & Wotton 1976) and its excretion in an unaltered, biologically active state in the urine, cefuroxime was studied to evaluate its efficacy and safety in patients suffering from urinary tract infections (UTI). Because of its stability to ,B-lactamases and high tissue levels, we also studied the effects of cefuroxime in patients with osteomyelitis.
PATIENTS AND METHODS

Urinary Tract Infections
Twenty-two patients with UTI were studied. Age, sex and clinical data on the patients are given in detail in Table 1 . All had been treated previously with other antibiotics, without success, but there was no antibiotic treatment prior to cefuroxime administration for at least I week except for case No. 21. Thirteen patients had evidence of chronic pyelonephritis from the history and radiographic evaluation. Nine patients, 6 of whom were pregnant, suffered from acute pyelonephritis. The pregnant patients with acute pyelonephritis had no history of previous pyelonephritis, but X-rays in order to investigate the urinary tract for obstructions could not be performed. The remaining 3 patients had no previous history and no radiographic abnormalities.
The criteria for assessing acute or exacerbation of chronic pyelonephritis were clinical examination, significant bacteriuria (exceeding 105/ml) and significant leucocyturia (Addis count more than 200,000/h, Table 2 ). Chronic pyelonephritis was assuLmed if the latter symptoms persisted longer than 3 months or recurred at least twice in a year. Attempts were made to show upper UTI by the bladder wash-out technique (Fairly et al. 1971 ) and by evidence of antibody coated bacteria using the immunofluorescence technique of Thomas et al. (1974) .
In cases of UTf, cefuroxime was administered in doses of 750-1000 mg every 8 h or 1000-2000 mg every 12 h. For i.m. injection, 750 or 1000 mg was dissolved in 5 ml of water for injection. For i.v. use the same amount was dissolved in 100 ml. The duration of therapy in UTI was 10-14 days, but in one patient only 7 days.
The therapeutic results were defined according to the urine cultures. The eradication of the original pathogen was taken to be a cure. A negative culture during therapy and more than 104 colonies/ml of the original organisms within 5 weeks after therapy was considered a relapse. Reinfection by an organism which was different from the one originally causing the infection was not regarded as a treatment failure but as another episode of infection.
All patients were observed closely during the course of therapy for side-effects. The following laboratory studies were performed before, during and after therapy: complete blood examination, liver function tests (serum glutamic-oxaloacetic transaminase, serum glutamic-pyruvic transaminase, alkaline phosphatase, lactic dehydrogenase and bilirubin), kidney function tests (blood urea nitrogen, serum creatinine and uric acid), urine analysis, culture of urine and Addis count. Urine culture and Addis count wvere followed up weekly until 5 weeks after treatment, then monthly.
Organisms were identified by standard microbiological methods. Sensitivity testing was carried out by the impregnated disc technique with cefuroxime discs containing 30 ,ug. Organisms with an inhibition zone of 15 mm diameter or more were considered sensitive. Bacteriologically, Escherichia coli was the predominating organism in 15 cases, followed by Klebsiella in 4 cases, Citrobacter, Proteus mirabilis, Streptococcus viridans and Staphylococcus aureus, each in 1 patient.
Results
At the completion of therapy all patients were asymptomatic with sterile urine. Of the 13 patients with chronic pyelonephritis, 9 were cured and 3 had a relapse 1-2 weeks later. Two of the cured patients had a reinfection after 3 and 4 weeks respectively. Patient 10, who had parapsoriasis lichenoides, developed erythema on the left leg after the fourth day of treatment. Therapy was discontinued because of the possibility of an allergic reaction. The erythema, however, was not related to antibiotic treatment. This patient had clinically recovered with disappearance of pain, fever and with sterile urine cultures. There was no recurrence by day 9 but the patient had to be discharged and no further examinations could be made. The effect of cefuroxime in this patient could not therefore be evaluated.
A second course of treatment in one patient with a relapse was unsuccessful. In all the patients who relapsed, there was no return of the leucocyte urine count to normal values during therapy.
Of the 9 patients with pyelonephritis, 5 were cured and 4 (3 of whom were pregnant) had a relapse. No reinfection occurred. In one patient with a relapse (104 colonies/ml of the original organism occurring within 5 weeks after therapy) a second course of treatment was again unsuccessful. Eleven out of 13 patients who received 2000 or 2250 mg/day did not relapse. Seven patients who had failed to respond to multiple previous antibiotic treatments within a short period received 4000 mg/day. Only 2 patients were cured, despite sensitivity of the originating organism.
Side-effects
No side-effects and no nephrotoxicity were seen. This also applied in the case of patients No. 5 and No. 12 who had decreased renal excretion rates, their creatinine clearance being 50 and 10 ml/min respectively.
Patient No. 15, known to have suffered from halothane hepatitis, showed a slight elevation of SGOT and SGPT. However, it was not necessary to discontinue therapy. No patient exhibited an allergic reaction to the medication. In all patients the i.v. and i.m. injections were well tolerated locally nor was any pain noted after i.m. injection of 1000 mg.
Osteomyelitis
Cefuroxime was additionally used as antibiotic treatment in 6 patients with acute exacerbation of chronic osteomyelitis. The clinical circumstances are given in Table 3 . With regard to Eetiology, case No. 5 was of hmematogenic origin; the others were following fractures, and the duration was 2-16 years. Again, all patients had previously been submitted to antibiotic treatment without success. Only in patients No. 2 and No. 6 could the originating pathogens be isolated, the other patients having no or sterile exudates. The organisms of the latter cases are listed in Table 3 and are those found in previous episodes of osteomyelitis.
Treatment was considered as effecting cure when the local symptoms disappeared together with scarring of the fistulas or surgical wounds. This relates only to the acute exacerbation, as a definitive cure in chronic osteomyelitis can only be assessed in patients who present no signs of reactivation during a follow-up for some years. The clinical response was considered as improvement when sterilization of the exudate took place and local signs of inflammation disappeared, but fistulas persisted. Opening up of new fistulas or development of definite abscess during therapy were regarded as failhre.
In cases of osteomyelitis, cefuroxime was given i.v. in doses of 2000-3000 mg every 12 h or i.m. in a dose of 1000-mg every 8 h. The duration of therapy was 16-22 days. All patients were closely followed up during and after treatment with the same controls as in the UTI cases. X-rays and bone scans were also performed.
Five out of 6 cases of osteomyelitis had a clinically favourable result. Two patients were considered to be cured and 2 showed marked improvement. None of them had a relapse during a follow-up period of 3-14 months. Patient No. 6 developed a subperiosteal abscess under therapy with 3000 mg of cefuroxime daily. The originating pathogen could be grown in the exudate. After incision and local drainage there was quick recovery without further antibiotic treatment. In patient No. 1, cefuroxime treatment was followed by intramedullary nail extraction with subsequent healing.
Again, no side-effects were seen, even after prolonged treatment with a dose of 6000 mg/day. Patient No. 6 complained of slight pain after i.m. injection of 1000 mg of cefuroxime.
Discussion
These groups of 22 patients with urinary tract infections and of 6 patients with osteomyelitis are not large enough nor sufficiently homogeneous to permit a definitive assessment of the therapeutic value of cefuroxime. But despite these deficiencies, this clinical trial did provide some insight into the efficacy and safety of the drug. A good therapeutic result was obtained in 15 out of 22 patients with UTI. In the patients with a relapse or reinfection this may be due to abnormalities of the urinary tract which together with poor host defences allow small numbers of organisms to survive and reinfect the urine. The higher dosage given in some patients and subsequent relapse suggest the presence of tissue involvement and show that adequate urine levels alone do not ensure eradication of pathogens. The effectiveness in osteomyelitis was less pronounced than in the UTI cases. However, in the latter host, factors such as tissue damage and vascular insufficiency play a much more important role.
The administration of cefuroxime was well tolerated both i.v. and i.m. Good tolerance was manifested locally and systematically. This was true despite the fact that several patients had prolonged courses of therapy or received such high doses as 6000 mg/day. Our experience suggests the value of further evaluation of cefuroxime to ascertain its proper position among the cepahlosporins currently available.
Summary
Twenty-two patients with pyelonephritis and 6 patients with osteomyelitis have been treated with cefuroxime. Out of 13 patients with exacerbation of chronic pyelonephritis, cure was achieved in 9. Out of 9 cases suffering from acute pyelonephritis, 5 were cured. Among the 6 patients with exacerbation of chronic osteomyelitis, 5 showed a favourable result.
Cefuroxime was well tolerated up to maximal doses of 6000 mg/day for 16 days. No nephrotoxicity, hematologic nor hepatic abnormalities were encountered. Only one out of 5 patients who received the drug i.m. mentioned slight pain after injection.
